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1. Introduction 
Neuroblastoma is a solid cancer that arises from precursor cells of the sympathetic 
nervous system. It is known for its extreme heterogeneity, ranging from spontaneous 
regression to rapid progression to metastasis. Prognostic factors include age and genetic 
abnormalities, with greater likelihood of survival in infants, suggesting that 
neuroblastoma is a developmental disorder (Jiang et al., 2011). Considering that 
neuroblastoma accounts for 15% of all cancer deaths among children, novel therapeutic 
targets are clearly needed. Furthermore, early differentiation of children who will not 
develop advanced-stage neuroblastoma would reduce long-term side effects due to 
treatment, improving quality of life of survivors. Since neuroblastoma arises from 
precursor cells, understanding the mechanism by which it becomes advanced-stage cancer 
might also provide insight into how normal stem cells transform into cancer stem cells. 
This chapter examines factors differentiating advanced, metastatic neuroblastoma from 
low-risk, localized neuroblastoma. 
Common genetic abnormalities in neuroblastoma include the genetic amplification (multiple 
DNA copies) of MYCN, chromosome 1p36 and 11q23 deletion, and the gain of chromosome 
17q22 (review in Jiang et al., 2011). Since all of these genetic abnormalities correlate with 
poor clinical outcome, they have been investigated as potential driving factors in advanced 
stage neuroblastoma. However, as advanced neuroblastoma also occurs without such 
genetic abnormalities, the signatures of advanced neuroblastoma must be determined to 
understand the mechanism of its progression. For example, though amplification of 
transcription factor MYCN was linked early on with a poor outcome (Bordow et al., 1998), 
MYCN status cannot fully account for all advanced-stage cases. In addition to DNA-level 
abnormalities, expression level changes of transcripts in advanced stage have been studied 
to accurately predict the disease outcome (Asgharzadeh et al., 2006; Oberthuer et al., 2006). 
However, MYCN transcript levels could not dependably identify advanced stage 
neuroblastoma either. It is clear that multiple gene regulation should be considered in 
deciphering neuroblastoma progression (De Preter et al., 2010; Overthuer et al., 2010). To 
differentiate the underlying mechanism of progression, several studies have assessed DNA 
abnormality and transcription level changes together, comparing, for example, all 
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transcription levels of advanced-stage neuroblastoma with and without MYCN 
amplification. Recent research on transcript-level changes has incorporated microRNA 
expression changes (Lin et al., 2010). 
MicroRNAs (miRNAs) are endogenous regulatory RNAs ranging in size from 16 to 25 
nucleotides that are processed from hairpin-structured precursors by the enzyme Dicer 
(Kim, 2005). Once a mature single strand miRNA becomes part of a miRNA-
RiboNucleoProtein complex (miRNP), it mostly functions as a negative regulator of other 
genes’ protein production by directly interacting with the target genes’ mRNAs in sequence-
complementary fashion. Though originally identified in terms of its translational repression 
function in animal, it also helps degrade target mRNAs themselves. So far, more than a 
thousand miRNAs have been identified in human (http://mirbase.org) (Kozomara & 
Griffiths-Jones, 2010), some of them potentially regulating about 200 genes (Lim et al., 2005). 
As with transcription factors and other endogenous genes with regulatory roles, expression 
of each miRNA is strictly controlled and exhibits characteristic patterns based on biological 
context, such as tissue type or developmental stages. In line with the critical roles of 
miRNAs in biological processes, their deregulation is frequently observed in many diseases, 
including neuroblastoma. 
Neuroblastoma-related miRNAs have been researched mainly in regard to two biological 
processes, anti-apoptosis (tumorigenesis), and epithelial mesenchymal transition (EMT: 
metastasis related). TP53 is a well-known transcription factor that induces apoptosis and 
miR-34 family transcription (He et al., 2007). In neuroblastoma, TP53 mutation is 
uncommon, whereas deletion on chromosome 1p36 (where mir-34a is located) frequently 
occurs. Another frequent deletion site of 11q23 coincides with mir-34b and mir-34c 
chromomal positions, implying the importance of the mir-34 family in neuroblastoma. On 
the other hand, MYCN amplification is frequent in neuroblastoma and several miRNAs are 
induced by MYCN, including the mir-17-92 cluster, which has been shown to be 
significantly upregulated in MYCN-amplified cells (Schulte et al., 2008) and has been 
identified with a direct anti-proliferation function (Matsubara et al., 2007). In 
neuroblastoma, upregulation of the mir-17-92 cluster is correlated with the obstruction of 
the TGF-beta signaling pathway, thereby preventing apoptosis (Mestdagh et al., 2010a). 
MYCN also achieves anti-apoptotic function by downregulating other miRNAs which 
prevent cell proliferation. Low levels of MYCN allow for the over-expression of miR-184, 
which has been shown to reduce neuroblastoma tumor growth (Foley et al., 2010; Tivnan et 
al., 2010). While MYCN affects transcripton of certain miRNAs, some miRNAs can down-
regulate MYCN translation, such as miR-34 (Christoffersen et al., 2010). let-7 and miR-101 
are also found to target MYCN and inhibit proliferation of MYCN-amplified neuroblastoma 
cells (Buechner et al., 2011). Similarly, Foley et al. demonstrate that miR-10a and miR-10b 
indirectly downregulate MYCN by targeting NCOR2, though the intermediate processes 
between NCOR2 and MYCN need further study (Foley et al., 2011). Therefore, miR-34 
family deletion and MYCN amplification in neuroblastoma together respond to 
tumorigenesis through anti-apoptotic process. 
Metastasis may also be brought on by altered levels of miRNA. Guo et al. show that 54 
different miRNAs are significantly altered in metastatic as opposed to primary 
neuroblastoma tumors (Guo et al., 2010). A more specific study showed that overexpression 
of miR-524-5p decreases the invasive potential of neuroblastoma cells (Bray et al., 2011). 
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Recently, the miR-34 family has been identified as blocking EMT by downregulating SNAI1 
(Kim et al., 2011), showing its dual function of blocking tumorigenesis and metastasis. Haug 
et al. found that miR-92 downregulates tumor suppressor DKK3 (Haug et al, 2011), which 
normally inhibits the Wnt signaling pathway. The canonical Wnt signaling can induce EMT 
mostly by degrading E-cadherin (Heuberger & Birchmeier, 2010). All this implies that a 
large network stretching across miR-34, MYCN, and the miR-17-92 cluster is responsible for 
both tumorogenesis and metastasis in neuroblastoma (Fig. 1). Hence, miRNAs hold promise 
as biomarkers for diagnostic and therapeutic purposes. 
 
 
 
 
 
 
Fig. 1. Schematic diagram of miRNA network in neuroblastoma tumorigenesis and 
metastasis, including miR-9 from this study. The dotted box represents our six predicted 
targets in this study. 
The problem remains that miRNAs’ small size and similar sequences often make their global 
expression data noisier than mRNA data. Given that miRNAs regulate the expression of 
target mRNAs, correlating miRNA with mRNA expression could increase biomarker 
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signals, leading to biomarkers with superior resolution and potentially revealing master 
regulators. To realize this potential, we need accurate miRNA target identification. While 
other areas of miRNA research have undergone continuous development, target prediction 
has lagged behind, partly due to the imperfect miRNA-mRNA bindings found in animals. 
As experimental and evolutionary evidence indicates that the 5’-end of miRNAs (the 
nucleotide position 1-8 at the 5’-end, also called the seed sequence) is important for 
recognition of target sequences in 3’-UTRs (untranslated regions) of mRNA, many 
computational algorithms utilize only 6-8 nucleotides (nt) of the ~22 mer miRNA to predict 
target mRNAs. However, there exist many genome-wide sequences matching this short 
stretch of 6-8 nt, resulting in a large number of false positives among the predicted targets 
and thus invalidating miRNA-mRNA correlations. Although a database of miRNAs and 
their experimentally verified targets exists (Papadopoulos et al., 2009), the list therein is still 
far from comprehensive. 
We have identified a new class of miRNA targets, called miBridge, in which the 5’- and 3’-
end of a miRNA can simultaneously interact with the 3’-UTR and 5’-UTR of a single mRNA 
(Lee et al., 2009). We will use the terms “3UTR:5emiR” (a miRNA seed sequence and its 
target site on the 3’-UTR: conventional knowledge) and “5UTR:3emiR” (the 3’-end of a 
miRNA—the other side of the seed region—and its recognition site in the 5’-UTR: our 
finding). Whereas other studies have not found global miRNA interactions with the 5’-UTR 
due to searching against the seed region (5UTR:5emiR), we have found significant 
5UTR:3emiR interactions (Ajay, et al., 2010; Lee et al., 2009). This sequence-specific 
miRNA function through 5UTR:3emiR has been experimentally validated (Lee et al., 
2009). In addition to these previous reports establishing the validity and utility of 
miBridge, we have recently generated a list of genome-wide miBridge targets using 
version 1 (v.1) prediction parameters. Interestingly, most known miRNA and mRNA 
(both 5’-UTR and 3’-UTR annotated) have miBridge interactions. Considering both ends 
of miRNA in the target prediction, miBridge targets are usually fewer in number (about 
1/2 to 1/10 of other predictions), while having specific functions which align well with 
previous expresimental data. 
In this chapter, we introduce a new approach to identifying miRNAs which differentiates 
high-risk (advanced) from low-risk neuroblastoma based on expression data and miBridge 
target predictions. When we applied the method to neuroblastoma patient datasets of 
mRNA and miRNA expression levels obtained from the Vandesompele group (Mestdagh et 
al., 2010b), we found miR-9 to be a consistent biomarker, all six predicted targets being 
downregulated and their expressions negatively correlated with miR-9 expression. This is 
interesting since MYCN is one of miR-9‘s transcription factors, though our analysis did not 
consider MYCN-amplification status in the advanced stage patient data group. Previous 
research has shown that miR-9 upregulation correlates with breast cancer metastasis (Ma et 
al., 2010), supporting our finding of miR-9 as a new biomarker for advanced neuroblastoma. 
Furthermore, we also found miR-9 to be significantly upregulated in short-term survival 
patients within the advanced stage neuroblastoma group in other publicly available data 
(Scaruffi et al., 2009), confirming the validity of our finding. To increase the specificity of 
differentiating high-risk and short-term survival groups, further research is needed to 
identify additional miR-9 activating factors besides MYCN as well as the common biological 
pathways of miR-9 target genes in neuroblasts (Fig. 1). 
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2. MicroRNA and target gene signature in advanced neuroblastoma 
Expression levels of mRNA depend on various factors including DNA copy number, 
DNA methylation, histone acetylation, active transcription factors, splicing factors, and 
regulating miRNAs. Here we analyze mRNA expression in a miRNA-centric manner, 
comparing it with miRNA expression data to increase the specificity of advanced 
neuroblastoma signatures. This is based on our hypothesis that if a miRNA’s function is 
important and causal to progress neuroblastoma and the expression of the miRNA is up 
(down)-regulated in the advanced stage, its targets will be preferentially down (up)-
regulated in the advanced neuroblastoma. Therefore, we will define a miRNA and its 
targets as important to the advanced neuroblastoma if such cases are found. Note that this 
method proceeds without bias of previous knowledge and simply searches for consistent 
expression data across different datasets (mRNA and miRNA expression), thus allowing 
novel findings. 
The Vandesompele group, which has recently identified correlations between MYCN-
induced miRNAs and poor outcome in MYCN-activated tumors (Mestdagh et al., 2010b), 
kindly provided us matching mRNA and miRNA expression patterns with an annotation 
file. We also downloaded the mRNA data, disease state, and MYCN amplification status 
from the Gene Express Omnibus (Series accession number GSE21713). The disease states 
followed the International Neuroblastoma Staging System‘s four stages. Stages 1 and 2 
indicating the cancer is still localized, while stages 3 and 4 indicate metastasis of the 
original tumor. To understand global genetic differences in advanced neuroblastoma, we 
defined two groups for comparison: stage 4 as one group and stage 1 and 2 as another, 
regardless of MYCN amplification status. Stage 3 data were excluded in order to obtain 
maximal contrast between the non-metastatic stages and metastatic stage 4. By comparing 
miRNA and mRNA expression of these two groups, we expected to obtain a more specific 
advanced neuroblastoma signature, which might not be apparent through mRNA or 
miRNA analysis alone. 
2.1 mRNA expression analysis 
2.1.1 Differently expressed mRNAs in advanced neuroblastoma 
In total, there are 30 primary tumor sample data from 14 stage 4 patients and 16 stage 1 and 
2 patients. Briefly, the Vandesomepele group derived the expression data as follows: after 
each sample expression dataset was obtained using GeneChip Human Exon 1.0 ST Arrays 
(Affymetrix), all exon data were combined to transcript clusters (hg18/core exons), to obtain 
expression information per gene after normalization according to the RMA-sketch algorithm 
using Affymetrix Power Tools. We used these RMA normalized data calculated by the 
Vandesomepele group to obtain differentially expressed genes between the two groups. 
Student t-tests were performed using Microsoft Excel functions and mRNA lists with p-
values less than 0.05 were prepared as up- and down-regulated mRNAs using HUGO Gene 
Nomenclature Committe (HGNC) gene symbol annotation. We ignored transcripts without 
gene symbol annotation or empty data points among patient samples. If more than two 
probe sets corresponded to one gene symbol, we chose the probe set with lower p-values. 
Among a total 372 up-regulated and 689 down-regulated mRNAs with gene symbols having 
p < 0.05, the top 50 genes with the greatest fold changes are shown in Table 1. 
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Down-
Regulated Gene
p-value 
Log2 (Fold 
Change) 
 
Up-Regulated 
Gene 
p-value 
Log2(Fold 
Change) 
ALCAM 0.012519 -1.1404  ACTA2 0.017706 0.84008 
APBA1 0.000975 -1.00703  BIRC5 0.007473 0.88797 
ATP2B4 0.008721 -1.02324  CCNA2 0.009386 0.79357 
CADM3 0.002402 -1.24665  CDC45L 0.007403 0.75931 
CDH6 0.049003 -1.01205  CDCA5 0.008474 0.77314 
DOC2B 0.013732 -1.02395  CMBL 0.004642 0.72441 
DRD2 0.001234 -1.08816  DDX1 0.046072 1.22142 
ECEL1 0.003074 -1.10837  E2F3 0.000912 0.74161 
EPB41L3 0.008477 -1.37384  FN1 0.008058 1.03848 
HIST1H1A 0.016193 -1.34667  FOXM1 0.008946 0.9346 
HS6ST3 0.000384 -1.10939  GJC1 0.002895 0.82971 
LRRTM4 0.040988 -1.31354  HIST1H2BM 0.037272 0.85818 
NRCAM 0.031584 -1.04967  HMGB2 0.006813 0.883 
NTRK1 0.001072 -1.79752  MAD2L1 0.012955 0.92231 
PGM2L1 0.010537 -1.14954  MYBL2 0.019576 0.82346 
PLXNC1 0.000939 -1.08949  MYCN 0.019589 1.23078 
PMP22 0.003898 -1.62031  NAG 0.020134 1.26792 
PRKCA 0.011104 -1.04588  ODC1 0.001326 1.3045 
PRPH 0.003777 -1.41955  PAICS 0.000609 0.74121 
PTN 0.00069 -1.19001  PHGDH 0.026183 0.88181 
RAB3C 0.025466 -1.00737  RRM2 0.00773 1.46016 
REEP1 0.002232 -1.00576  SLC16A1 0.000721 0.93447 
SCG2 0.009003 -1.21159  TYMS 0.016238 0.95479 
SCN9A 0.0207 -1.02774  VCAN 0.019634 0.99934 
SYN3 0.006658 -1.04893     
TMEM176A 0.006741 -1.11877     
Table 1. Top 50 genes with the greatest fold changes among differently expressed mRNAs in 
advanced neuroblastoma (p < 0.05). 
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2.1.2 Mapping differentiated mRNAs to regulating miRNAs 
For all mRNAs identified as differentially regulated, their regulating miRNAs were 
predicted using the miBridge miRNA target prediction method (v.1).We then calculated 
enrichment scores for miRNAs based on their target enrichment tests among the 
differentially regulated mRNAs. Score over 0 means that the predicted miRNA is significant 
in the system, 1 being optimal. Table 2 shows the predicted regulating miRNAs (within the 
miRNA list in the array measured) with target enrichment score over 0. Within the mir-17-
92 cluster, hsa-miR-18* targets are enriched in the down-regulated mRNAs, supporting our 
hypothesis and miRNA target predictions (though miR-92a is not included in this p < 0.05 
list, inclusion of genes with less than 15 empty values in patient samples yields a miR-92a 
score of 0.04 and the prediction that it is up-regulated in advanced neuroblastoma 
 
Regulating miRNA 
Enrichment 
score 
Predicted as 
hsa-miR-9 0.03642 up 
hsa-miR-18a* 0.3787 up 
hsa-miR-136 0.3765 up 
hsa-miR-152 0.03642 up 
hsa-miR-185 0.7552 up 
hsa-miR-205 0.49874 up 
hsa-miR-214 0.46397 up 
hsa-miR-221 0.73754 up 
hsa-miR-324-3p 0.49392 up 
hsa-miR-326 0.97012 up 
hsa-miR-328 0.86602 up 
hsa-miR-346 0.51208 up 
hsa-miR-500 0.03642 up 
hsa-miR-610 0.08688 up 
hsa-miR-650 0.81604 up 
hsa-miR-489 0.64438 down 
Table 2. Predicted miRNAs as potential regulators of advanced neuroblastoma (enrichment 
score > 0). 
2.2 miRNA expression analysis 
The miRNA expression data were obtained from the same patient samples analyzed in the 
mRNA expression: total 14 stage 4 patients and 16 stage 1 and 2 patients. We used the RMA 
normalized data with 312 mature miRNA annotations as provided by the Vandesomepele 
group. Student t-test was performed using Microsoft Excel functions; miRNA lists of score > 0 
are shown in Table 3. 
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up-regulated 
miRNA 
p-value 
Log2 (fold 
change) 
down-regulated 
miRNA 
p-value 
Log2 (fold 
change) 
hsa-miR-9 0.037541 1.173707 hsa-miR-15a 0.044916 -0.49254 
hsa-miR-9* 0.018107 1.235894 hsa-miR-24 0.030286 -0.44341 
hsa-miR-18a 0.02853 0.570961 hsa-miR-26a 0.007846 -0.53493 
hsa-miR-18a* 0.001933 0.58714 hsa-miR-26b 0.011224 -0.44942 
hsa-miR-19a 0.038493 0.588543 hsa-miR-30a-3p 0.023514 -0.68173 
hsa-mir-92 0.006916 0.782683 hsa-miR-30b 0.00698 -0.50628 
hsa-miR-105 0.036113 1.681312 hsa-miR-30e-3p 0.023054 -0.77332 
hsa-miR-320 0.023005 0.362074 hsa-miR-95 0.012503 -0.91388 
hsa-miR-375 0.03906 1.901862 hsa-miR-103 0.0395 -0.35021 
hsa-miR-517a 0.045293 1.423221 hsa-miR-125b 0.00271 -0.89665 
hsa-miR-520g 0.024751 1.757529 hsa-miR-128a 0.016545 -0.73381 
hsa-miR-526b* 0.049281 0.601139 hsa-miR-137 0.000167 -1.78508 
hsa-miR-645 0.014262 0.758181 hsa-miR-140 0.010729 -0.3409 
hsa-miR-148b 0.009921 -0.56818 
hsa-miR-149 0.002849 -1.13549 
hsa-miR-190 0.048211 -1.23233 
hsa-miR-204 0.008341 -2.21371 
hsa-miR-215 0.005819 -1.68041 
hsa-miR-216 0.042686 -1.38497 
hsa-miR-218 0.045402 -0.86703 
hsa-miR-324-3p 0.034135 -0.52073 
hsa-miR-324-5p 0.028667 -0.74833 
hsa-miR-326 0.048664 -0.71389 
hsa-miR-330 0.010354 -0.98399 
hsa-miR-331 0.004691 -0.73239 
hsa-miR-340 0.010086 -0.77428 
hsa-miR-488 0.01028 -1.08969 
hsa-miR-491 0.042597 -0.68084 
hsa-miR-628 0.000553 -1.00498 
Table 3. Differentially expressed miRNAs in the advanced neuroblastoma (student t-test p < 
0.05) 
We found that two miRNAs predicted as up-regulated with enrichment score > 0, miR-9 
and miR-18a*, are actually up-regulated in microarray experiments with student t-test p < 
0.05. Since miR-18a* is a minor strand (less present than miR-18a) within the mir-17-92 
cluster, we conclude that miR-9 is the most consistent miRNA in terms of its expression and 
its targets’ expression in our analysis. Fig. 2 shows the box plots of miR-9 expressions in 
advanced and low-risk stage patient samples together with five other miRNAs whose 
expression values are most significantly changed in up- and down-regulated miRNAs. 
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Fig. 2. Box plots of miR-9 (A), miR-18a* (B), miR-92 (C), miR-125b (D), miR-137 (E), and miR-
149 (F) expression between advanced and low-risk stage neuroblastoma patient samples. 
2.3 Correlation of mRNA and miRNA expression data 
We found miR-9 to have the most consistent signal in terms of miRNA and mRNA 
expression level changes in advanced neuroblastoma. Note that miRNA expression 
pattern alone does not justify further in-depth analyses of miR-9 since other miRNAs have 
higher fold changes or lower p-value. Our approach thus provides a new way to prioritize 
important miRNAs. Interestingly, miR-9’s seven predicted targets genes are found only in 
the down-regulated genes. However, this does not mean that expressions of miR-9 and its 
target genes are negatively correlated across entire samples. Fig. 3 shows the Pearson 
product moment correlation coefficient of miR-9 and its seven target genes across the 30 
patient samples. For context, correlations between miR-9 and all mRNA expression are 
also shown. The correlations of miR-9 and target genes stand out from all other 
correlations, six of the seven targets being negatively correlated with miR-9. The six 
negatively correlated predicted targets are AGPAT4, BTBD9, GABBR1, KCNK10, 
LRRTM4, and S100PBP. Among them, LRRTM4 is in Table 1, containing top 50 greatest 
fold change genes. Fig. 4 shows the scatter plots of the two most negatively correlated 
miR-9 target genes. 
Though miR-9 can target multiple genes at the same time, the expression of each target 
gene varies from person to person, so that its function on each target gene might vary 
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among patients. In our analysis, six genes are predicted as functional targets in the 
neuroblastoma, potentially responsible for disease progression. As an example, some 
outliers shown in the circle in Fig. 4B are no longer outliers in the S100PBP case in Fig. 4A. 
Therefore, rather than one miRNA or one miRNA and its target, collective miR-9 targets 
and miR-9 might allow more accurate prediction of whether a neuroblastoma will 
progress to advanced stage. 
 
 
Fig. 3. Histogram of Pearson correlation values between miR-9 and gene expressions. The 
red bars show miR-9 target genes found in the down-regulated genes; blue bars represent all 
genes measured in the microarray experiments (total 1,4159 genes excluding ones with 
blank data > 5 among samples). 
 
 
Fig. 4. Scatter plots showing miR-9 and target gene expressions for 30 patient samples. 
Pearson correlation coefficient of miR-9 and S100PBP is -0.53 (A) and that of miR-9 and 
LRRTM4 is -0.48 (B). 
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3. miR-9 signature in short - and long - lived patients 
Scaruffi et al. published research on non-coding RNA expressions with regard to outcome 
in high-risk neuroblastoma (Scaruffi et al., 2009). Among 31 high-risk, stage 4 
neuroblastoma samples, miRNA expressions came from 17 short-term survivors (dead 
within 36 months from diagnosis) and 14 long-term survivors (alive with an overall 
survival time > 36 months) were deposited in GEO (Series accession number GSE16444). 
We downloaded the data, which were log2-transformed and quantile normalized, after 
obtaining the raw data using miRNA microarray System protocol v. 1.5 (Agilent 
Tenchnologies). Since they removed probes with less than 50% of detected slops across all 
arrays, many low signals were not present. We used the downloaded data to identify 
differential miRNAs between short- and long-term survivor groups. Significance was 
calculated with a student’s t-test (unpaired, two-tailed, unequal variance); miRNAs up- 
and down-regulated in short-term survivors with p-values less than 0.05 are shown in 
Table 4. 
 
up-regulated 
miRNA 
p-value 
Log2 (fold 
change) 
down-
regulated 
miRNA 
p-value 
Log2 (fold 
change) 
hsa-miR-9 0.0377472 0.68625181 hsa-miR-22 0.040065 -0.990610191 
hsa-miR-210 0.0284823 1.147684424 hsa-miR-139-3p 0.0478034 -0.803202819 
hsa-miR-425 0.0127439 0.62221312 hsa-miR-181c* 0.0497988 -1.015817709 
hsa-miR-758 0.0080157 1.01630988 hsa-miR-302a 0.0338064 -0.915468934 
hsa-miR-885-5p 0.0117879 1.125425787 hsa-miR-502-3p 0.0481067 -0.69939469 
hsa-miR-885-3p 0.0118758 0.669348934 hsa-miR-886-3p 0.0424204 -1.691328238 
hsa-miR-877 0.0276158 0.571214174 
hsa-miR-936 0.0388439 0.656436824 
Table 4. Differentially expressed miRNAs in short-term survivors compared with long-term 
survivors. All patients had advanced neuroblastoma. 
Due to the distinct difference between diseased and healthy status, the overall number of 
differentially expressed miRNAs with a certain p-value cutoff may be much greater than 
that within the disease group. Within the disease group, though neuroblastoma has diverse 
outcomes, differentiating stages within the neuroblastoma is more difficult than 
differentiating disease from normal. To increase differentiating power, we did not include 
stage 3 neuroblastoma data in our section 2 analysis. Here, we further differentiate a 
narrower range within stage 4. Therefore, it is not surprising that fewer miRNAs were 
differentiated here than between advanced and low-risk neuroblastoma. Also, it is common 
for different research groups to produce differing lists of significantly changed genes. 
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However, if underlying causes exist for advanced neuroblastoma which further lead to 
short-term survival, we might identify them from a persistent signal in various contexts. We 
find miR-9, the only miRNA common between Table 3 and 4, to be such a consistent signal. 
We want to emphasize that miR-9 must be evaluated in connection with target gene 
expressions. It was found to be the most consistent miRNA in terms of down-regulating 
target mRNAs when induced. Moreover, its expression differs between short- and long-term 
survivors. When it comes to identifying miRNA signature from expression data, it is 
therefore crucial to compare a miRNA’s target expression patterns with its own expression. 
While many studies focus on global correlations between miRNA and mRNA expressions 
without a clear regulating matrix, our method of assessing consistency clearly helps 
pinpoint the signature miRNA in the disease progression. 
 
 
Fig. 5. Box plots of miR-9 (A), miR-758 (B), miR-885-5p (C), miR-22 (D), miR-302a (E), and 
miR-886-3p (F) expressions of neuroblastoma between short- and long-term survivors in 
advanced stage patients. 
Fig. 5 shows the box plot of miR-9 and five other miRNA expressions (chosen in order of 
smaller p-values) of samples from short- and long-term survivors in the Table 4. Though the 
p-value of miR-9 is not as low as others, its differentiating power is close to that of miR-758. 
In Fig. 2, the miR-9 level itself may not be powerful enough to differentiate advanced stage 
from low-risk neuroblastoma. Here, the data suggest that the broader range of miR-9 
expression in advanced stage is due to its differentiating power between two sub-groups of 
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advanced stage patients (absolute number of normalized data in each dataset is not 
meaningful). In terms of early prognostic power, miR-9 and its targets hold high promise. 
Further investigation using larger samples is needed. 
4. miR-9 functional model in advanced neuroblastoma 
Recently, Ma et al. reported that miR-9 directly targets E-cadherin (CDH1), leading to 
increased cell motility and invasiveness in breast cancer (Ma et al., 2010). Though in a 
different cell type, since the function of CDH1 in solid tumors is the same, we expect miR-9 
to function similarly in the neuroblastoma. Moreover, as a MYCN-activated miRNA, miR-9 
fits well within the neuroblastoma miRNA networks (Fig. 1) as a function of developing 
advanced metastasized neuroblastoma. Our identification of miR-9 and its targets thus 
makes sense functionally as an early prognostic marker for developing high mortality 
neuroblastoma. Fig. 1 includes miR-9 and CDH1 as a functional model of developing 
advanced stage neuroblastoma. 
5. Conclusion 
We have used our new method to analyze mRNA and miRNA expression data to identify 
signature miRNA and target genes in stage 4 neuroblastoma. To obtain maximal contrast 
between the non-metastatic stages and metastatic stage 4, we excluded stage 3 data and 
combined stage 1 and 2 as low-risk. When we compared advanced and low-risk stage 
neuroblastoma, miR-9 related expressions had the most consistent data between mRNA 
and miRNA expression. We also confirmed that six out of the seven predicted targets 
were negatively correlated with miR-9 expression across entire samples. Furthermore, 
miR-9 expression was significantly up-regulated in samples from short-term survivors 
compared with those from long-term survivors within the same advanced-stage 
neuroblastoma group. In addition to these data-driven analyses, note that miR-9 has been 
identified as inducing metastasis in breast cancer by targeting E-cadherin. Therefore, our 
claim of expressions of miR-9 and its targets as a signature of advancing neuroblastoma 
fits well with previous studies. Further investigation with a larger number of samples is 
needed. 
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